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Abstract
Background: Tamoxifen is used in hormone therapy for estrogen-receptor (ER)-positive breast cancer, but also has
chemopreventative effects against ER-negative breast cancers. This study sought to investigate whether oral
iron-saturated bovine lactoferrin (Fe-Lf), a natural product which enhances chemotherapy, could improve the
chemotherapeutic effects of tamoxifen in the treatment of ER-negative breast cancers.
Methods: In a model of breast cancer prevention, female Balb/c mice treated with tamoxifen (5 mg/Kg) were fed
an Fe-Lf supplemented diet (5 g/Kg diet) or the base diet. At week 2, 4T1 mammary carcinoma cells were injected
into an inguinal mammary fat pad. In a model of breast cancer treatment, tamoxifen treatment was not started
until two weeks following tumor cell injection. Tumor growth, metastasis, body weight, and levels of interleukin 18
(IL-18) and interferon γ (IFN-γ) were analyzed.
Results: Tamoxifen weakly (IC50 ~ 8 μM) inhibited the proliferation of 4T1 cells at pharmacological concentrations
in vitro. In the tumor prevention study, a Fe-Lf diet in combination with tamoxifen caused a 4 day delay in tumor
formation, and significantly inhibited tumor growth and metastasis to the liver and lung by 48, 58, and 66%
(all P < 0.001), respectively, compared to untreated controls. The combination therapy was significantly (all P < 0.05)
more effective than the respective monotherapies. Oral Fe-Lf attenuated the loss of body weight caused by
tamoxifen and cancer cachexia. It prevented tamoxifen-induced reductions in serum levels of IL-18 and IFN-γ, and
intestinal cells expressing IL-18 and IFN-γ. It increased the levels of Lf in leukocytes residing in gut-associated
lymphoid tissues. B, T and Natural killer (NK) cells containing high levels of Lf were identified in 4T1 tumors,
suggesting they had migrated from the intestine. Similar effects of Fe-Lf and tamoxifen on tumor cell viability were
seen in the treatment of established tumors.
Conclusions: The results indicate that Fe-Lf is a potent natural adjuvant capable of augmenting the
chemotherapeutic activity of tamoxifen. It could have application in delaying relapse in tamoxifen-treated breast
cancer patients who are at risk of developing ER-negative tumors.
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Background
Breast cancer is the most common cause of cancer death
in women worldwide [1]. Tamoxifen has been employed
for over 20 years as the drug of choice for the treatment
of estrogen receptor positive (ER+ve) breast cancer [2,3].
Despite providing a considerable initial benefit to at least
half of all patients, the majority of breast cancers even-
tually become resistant to the cytostatic effects of tam-
oxifen within 5 years of treatment [4], leading to an
increased risk of development of ER-ve breast cancers [4-6],
particularly contralateral cancers [7]. The outgrowth of
triple negative “basal-like” tumor cells lacking the ER, pro-
gesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2) is particularly concerning as
patients with these tumors have a poor prognosis [8]. Loss
of effectiveness of tamoxifen is problematic for breast can-
cer survivors undergoing long-term therapy as tamoxifen
inhibits the immune response which might otherwise help
to keep their cancers in-check. Tamoxifen treatment
downregulates the expression of the cytokine interleukin
(IL)-18 [9], lowers the numbers of CD4+ T cells [10], and
reduces natural killer (NK) cell activity [10]. It inhibits the
functions of monocytes, antibody formation, dendritic cell
differentiation and activation, and reduces lymphoid organ
weights in rodents [11-14]. It upregulates the expression of
the potently immunosuppressive cytokine transforming
growth factor (TGF)-β1 in breast tumors, which tumors
use to avoid the immune response, and is implicated in the
failure of tamoxifen therapy [15]. Upregulation of TGF-β1
is also seen with the ER antagonist fulvestrant, suggesting
it may be a common feature of several anti-estrogens [16].
The potential detrimental effects that tamoxifen has
on patients at risk of developing ER-ve breast cancers
might be worse were it not for the fact that tamoxifen
displays chemopreventative activity, due to off target
effects. Like many small molecule inhibitors, tamoxifen
is not a highly selective drug. It has been reported to dis-
play anti-tumor activity against ER-ve breast cancers, and
other unrelated cancers [17-19]. Pharmacological con-
centrations of tamoxifen induce proapoptotic effects in
ER-ve breast cancer cells, via the activation/inactivation
of signaling pathways that involve phosphatidylinositol
3-kinase (PI3K)/Akt, extracellular-signal-regulated kin-
ase (ERK), and insulin-like growth factor 1 receptor
(IGF-1R) [20]. The chemopreventative effects of tamoxi-
fen against ER-ve breast cancer cells and tumors have
been demonstrated by using tamoxifen alone or in syn-
ergistic combinations with various natural products and
chemical agents including epigallocatechin gallate [21],
docetaxel, genistein, black cohosh, palm oil tocotrienols,
OSU-03012 (latter studies are cited in ref 21), roscovitine
[22], persin [23], flax seed enterodiol and enterolactone
[24], mifepristone [25], interferons [26] and tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) [27].
Tamoxifen in combination with paclitaxel has a cytotoxic
effect against ER-ve colon cancer and lung cancer cell lines
[28]. One approach to bolster the chemopreventative
effects of tamoxifen is to use immunotherapy, which may
help overcome tamoxifen-induced immunosuppression.
Thus, IFN-γ and IL-2 immunotherapy significantly
improved the clinical response and survival of breast can-
cer patients treated with tamoxifen [29,30].
Lactoferrin (Lf) is an iron-binding glycoprotein present
in bodily secretions, which serves as a natural antibiotic,
but also has anti-tumor activity [31,32]. Lf-induced anti-
tumor activity was lost in mice depleted of CD8+ T cells
and in CD1 knockout mice lacking NK T cell activity,
suggesting Lf functions by stimulating anti-tumor im-
munity [33]. Oral Lf accelerated reconstitution of humoral
and cellular immune responses during chemotherapy-
induced immunosuppression in mice [34,35], suggesting
it could be employed to overcome tamoxifen-induced
immune suppression.
We recently showed that iron-saturated Fe-Lf was su-
perior to natural bovine Lf (bLf ) in stimulating anti-
tumor immunity and inhibiting tumor growth, especially
when used in combination with chemotherapy [36].
Further, it reduced the side-effects of chemotherapy by
restoring red and white blood cell counts. Here we
investigated the ability of Fe-Lf to improve the che-
motherapeutic effects of tamoxifen against 4T1 tumors
that express low levels of ER, PR, and HER2, and repre-




Female 6–8 week old Balb/c mice were obtained from the
Animal Resource Unit, Faculty of Medical and Health
Sciences, University of Auckland, Auckland, New Zealand.
They were kept in an air-conditioned room with controlled
humidity, temperature, and 12 h light: dark cycle. All
experiments were conducted under a protocol approved by
the Animal Ethics Committee, University of Auckland. The
mouse 4T1 mammary carcinoma cell line (Balb/c origin),
which was purchased from the American Type Culture
Collection (Rockville, MD, USA) very weakly expresses the
ER [37] and is non-responsive to estrogen [38]. Tamoxifen
at 5 μg/ml significantly inhibited the viability of 4T1 cells in
culture at 48, 72, 96, and 120 hour time periods, and signifi-
cantly increased the life-span of mice inoculated with 4T1
tumor cells [39].
Antibodies
The primary Abs used in this study included a mouse
anti-bovine Lf Ab (Hycult Biotechnology, Frontstraat 2a,
5405 PB Uden, The Netherlands), a rat anti-mouse
CD11b Ab (monocyte/macrophage marker, BD Biosciences,
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NJ), a mouse anti-mouse PK136 Ab (NK cell marker,
Biolegend, San Diego, CA), rat anti-mouse IL-18 and
IFN-γ Abs (BD Biosciences), a rat anti-mouse CD3 Ab
(T cell marker, Biolegend), a rat anti-mouse B cell mar-
ker Ab (Serotec, Oxford, UK), and a rat anti-mouse
dendritic cell marker Ab (eBioscience, San Diego, CA).
The secondary Abs used in this study included a fluor-
escein isothiocyanate (FITC)-conjugated rat anti-mouse
IgG (Sigma), an alexa fluor 568-conjugated donkey
anti-mouse Ab and an alexa fluor 568-conjugated goat
anti-rat Ab (Invitrogen, Auckland, New Zealand).
Experimental diets
Bovine Lf that had been saturated with iron to 100%
using an industrial scale food grade method was provided
by Fonterra Co-operative Group Limited, New Zealand.
The experimental diets were prepared according to the
Harlan Teklad AIN93M base formulation. The Fe-Lf diet
was produced by partial substitution of the casein compo-
nent of the control diet with Fe-Lf (5 g/Kg diet), such that
the total protein content of the diet was unchanged. The
compositions of the control and Fe-Lf diets are shown in
Table 1. The mice were provided with fresh diet thrice
per week, and they had free access to food and water
throughout the study.
Experimental animal models and treatments
In the prevention experiment, 72 six-week-old Balb/c
female mice were randomized into four groups of 18
animals each, to receive either the control diet, control
diet + tamoxifen, Fe-Lf diet, or Fe-Lf diet + tamoxifen.
The feeding schedules are shown in Figure 1A. In the con-
trol diet and Fe-Lf diet groups, the mice were fed with
control or Fe-Lf diets, respectively, and received an i.p.
injection of 100 μL of PBS every two days. In the control
diet + tamoxifen and Fe-Lf diet + tamoxifen groups, the
mice were fed with control and Fe-Lf diets, respectively,
and received an injection of 100 μL of tamoxifen (Sigma,
MO) suspension at a dose of 5 mg/Kg body weight every
two days. The tamoxifen powder was initially dissolved in
100% ethanol, and then diluted in PBS to prepare a
tamoxifen injectable suspension. Tamoxifen was injected
subcutaneously on the inside of either thigh with the sites
of injection being rotated. Fourteen days later, 50 μl of a
mixture of BD Matrigel™ Basement Membrane Matrix
(BD Biosciences) and PBS (phosphate buffered saline)
(1:1, v/v) containing 2 × 104 4T1 cells was injected into
the right inguinal mammary fat pad of mice. The mice
were monitored and weighed, and the sizes of the tumors
were recorded by measuring tumor diameters. Six mice in
each group were killed at the indicated time points
(Figure 1A), bled by cardiac puncture and sera isolated.
Tumors, lungs, livers, small intestines, gastrocnemius
muscles and ovarian adipose tissues were excised and
weighed.
In the treatment experiment (Figure 1A), 24 mice were
randomized into four groups of 6 mice as in the preven-
tion experiment, but the injections of tamoxifen or PBS
were started when the tumors reached ~0.2 to 0.3 cm in
diameter, 14 days after injection of 4T1 cells.
Measurement of tumor metastases
The numbers of metastatic tumors on the lung surface
were counted. The livers were fixed with 4% buffered
formalin solution and transverse 5-μm sections were
prepared at 5 different levels to cover the entire liver.
The sections were stained with haematoxylin and eosin
(HE), metastatic nodules containing more than 6 cancer
cells were counted, and the mean number of nodules
was recorded as the number of metastases.
Immunohistochemical analysis
Formalin-fixed tissues were embedded in paraffin and
sectioned. After antigen retrieval, the slides were rehy-
drated, and blocked with 5% casein in PBS containing
2% normal horse serum or 2% BSA (bovine serum albu-
min) at 4°C overnight. The sections were incubated with
primary Abs overnight at 4°C, followed by incubation with
appropriate secondary Abs for 1 h at room temperature.
They were then washed and mounted, and examined using
a Nikon E600 fluorescent microscope.
Enzyme-linked immunosorbent assay (ELISA)
Serum levels of IL-18 and IFN-γ were measured with
mouse IL-18 and IFN-γ ELISA kits (R&D Systems),
respectively.
Table 1 Compositions of experimental diets*




Corn starch 463.38 463.38
Maltodextrin 154.23 154.23
Sucrose 99.5 99.5
Soybean oil 39.8 39.8
Cellulose 49.75 49.75
Mineral mix, AIN-93 M-MX (94049) 34.83 34.83
Vitamin mix, AIN-93-VX (94047) 9.95 9.95
Choline bitartrate 2.49 2.49
TBHQ, antioxidant 0.008 0.008
*The diets were prepared based on the Harlan Teklad AIN-93 M
(TD 94048) diet. TBHQ, tert-butylhydroquinone; Fe-Lf, iron-saturated bovine
lactoferrin (100% iron-saturated).
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MTT assay
4T1 cells (2 × 103) were seeded in 200 μl of RPMI 1640
medium into 96-well plates, and cultured overnight. The
medium was replaced with the fresh RPMI 1640
medium or the same media containing tamoxifen. After
a further incubation for 72 h, methyl thiazolyl tetrazo-
lium (MTT) (20 μl) was added to each well followed by
a 4 h incubation. The medium was discarded and 150 μl
of dimethyl sulfoxide (DMSO) was added into each well,
and incubated for 20 min. The optical density (OD) was
measured at 490 nm. The cell viability index was calculated
according to the formula: experimental OD value/control
OD value × 100%. The experiments were repeated thrice.
Statistical analysis
Results were expressed as mean values ± standard devi-
ation (SD). A one way analysis of variance (ANOVA) fol-
lowed by Dunnett’s test (PASW statistics 18) was used
for evaluating statistical significance. P < 0.05 was con-
sidered to be statistically significant.
Results
Tamoxifen reduces the viability of 4T1 cells in vitro
The chemotherapeutic effect of tamoxifen on the viabil-
ity of 4T1 cells was examined by incubating 4T1 cells
with different concentrations of tamoxifen for 72 h. As
shown in Figure 1B, tamoxifen at concentrations of
1 μM and greater inhibited the viability of 4T1 cells,
with an IC50 of 8.1 μM.
Bovine Fe-Lf augments tamoxifen therapy to inhibit the
formation and growth of basal-like breast tumors
Groups of Balb/c mice were placed on either the control
diet or the Fe-Lf diet, and received injections of either
PBS or tamoxifen every two days to determine whether
Fe-Lf would augment the effects of tamoxifen in pre-
venting the formation of breast tumors (Figure 1A).
Fourteen days after starting the treatments, 4T1 breast
tumor cells were injected into the right inguinal mam-
mary fat pad. Neither the Fe-Lf nor tamoxifen monother-
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Figure 1 Experimental protocols for prevention and treatment models of breast cancer, and sensitivity of 4T1 cells to tamoxifen. A:
Experimental protocols. In the prevention model, mice were placed on the control diet or the Fe-Lf diet, and 4T1 tumor cells were injected into
the mammary fat pad 14 days later. Tamoxifen or PBS was administered i.p. on the day the mice were placed on their diets, and on alternate
days thereafter. Six mice per group (n = 18) were randomly killed at the indicated time points. In the treatment model, the mice were placed on
the diets and 4T1 cells were injected into the mammary fat pad 14 days later. Tamoxifen or PBS was administered 14 days after injection of
tumor cells, and on alternate days thereafter. Each group had 6 mice, which were killed at the completion of the experiment. B: Tamoxifen has
chemotherapeutic effects against 4T1 cells. 4T1 cells were incubated with increasing concentrations of tamoxifen, and their viability assessed 72 h
later by the MTT assay. The cell viability index (% viability) was plotted versus the concentration of tamoxifen.
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whereas in contrast the combination of the Fe-Lf diet and
tamoxifen delayed the appearance of palpable tumors by
4 days, and inhibited their growth compared with the
control diet (Figure 2A). Consequently, on day 43 the
tumors formed were on average 48% smaller (P < 0.001)
than the tumors in the control diet group, and were sig-
nificantly (P < 0.05) smaller than tumors of the monother-
apy groups (Figure 2A). Nevertheless, each of the Fe-Lf
and tamoxifen monotherapies inhibited tumor growth,
resulting in significantly (both P < 0.05) smaller tumors
on day 43 than the tumors of mice fed the control diet.
The size of tumors was in accordance with the weight of
tumors as shown in Table 2. To investigate whether the
effects of the combination of the Fe-Lf diet and tamoxifen
were synergistic, we calculated the value for the coeffi-
cient of drug interaction (CDI), as described previously
[40]. The CDI value on day 43 was 0.9 (less than 1), indi-
cating that Fe-Lf and tamoxifen have a synergistic effect
in inhibiting tumor growth.
In the treatment experiment (Figure 2B), mice were
placed on their diets, and 14 days later 4T1 cells were
injected into a mammary fat pad. They received injec-
tions of either PBS or tamoxifen every two days when
their tumors reached ~0.2 to 0.3 cm in diameter 14 days
after injection of the 4T1 cells. Similar results were
obtained as in the prevention experiment, where the Fe-Lf
and tamoxifen therapies each significantly (P < 0.05) sup-
pressed the growth of tumors (Figure 2B). Again the com-
bination of Fe-Lf and tamoxifen proved to be the most
effective, having a significant (P < 0.05) effect compared to
the monotherapies, with a CDI of 0.9.
Fe-Lf augments tamoxifen therapy to suppress the
dissemination of tumor metastases to the liver and lung
Suppression of liver metastases
The 4T1 breast cancer cell line is highly metastatic and
disseminates to the lung and liver while the primary
tumor is growing in situ [41]. The livers of mice in the
prevention experiment (Figure 2A; day 43) were sec-
tioned and stained, and the numbers of metastatic
nodules inside the livers were counted. The mean num-
ber of metastases in the liver sections of untreated mice
fed the control diet, tamoxifen-treated mice fed the con-
trol diet, untreated mice fed the Fe-Lf diet, and
tamoxifen-treated mice fed the Fe-Lf diet, was 118, 76,
91 and 50, respectively (Figure 2C). Thus, tamoxifen
therapy and the Fe-Lf diet each significantly (P < 0.05)
reduced the numbers of tumors in the liver by 36% and
23%, respectively, compared with untreated mice fed the
control diet. The Fe-Lf diet in combination with tamoxifen
therapy was the most effective, reducing tumor numbers
by 58% (P < 0.001), 45% (P < 0.05), and 34% (P < 0.05),
compared with untreated mice fed the control diet,
untreated mice fed the Fe-Lf diet, and tamoxifen-treated
mice fed the control diet, respectively.
Suppression of lung metastases
The surfaces of the lungs of the mice in the prevention
experiment (Figure 2A; day 43) were inspected for the
presence of metastatic 4T1 tumors. The mean number
of metastatic tumors on the lungs of untreated mice fed
the control diet, tamoxifen-treated mice fed the control
diet, untreated mice fed Fe-Lf diet, and tamoxifen-
treated mice fed Fe-Lf diet, was 29, 19, 21 and 11, re-
spectively (Figure 2D). Thus, tamoxifen treatment and
the Fe-Lf diet each significantly (P < 0.01) reduced the
numbers of tumors on the lung surface by 34% and 28%,
respectively, compared with untreated mice fed the con-
trol diet. The Fe-Lf diet in combination with tamoxifen
therapy was the most effective, reducing tumor numbers
by 66% (P < 0.001), 48% (P < 0.05) and 42% (P < 0.05), re-
spectively, compared with untreated mice fed the control
diet, untreated mice fed the Fe-Lf diet, and tamoxifen-
treated mice fed the control diet. The numbers of lung
metastases were in accordance with the weight of the
lungs, where increased numbers of metastases correlated
with increased organ weight, as shown in Table 2.
Oral Fe-Lf attenuates loss of body weight caused by
cancer cachexia and tamoxifen therapy
The 4T1 tumor model represents a model of late-stage
breast cancer and cancer cachexia. The body weights of
all four groups of mice in the prevention experiment
(Figure 2A) began to decline once the tumors reached
around 0.2 cm in diameter at day 29, possibly because of
the increasing cachectic status of the mice (Figure 2E).
Untreated tumor-bearing mice fed the control diet
experienced a significant (P < 0.05) 12% reduction in
carcass body weight at day 43 compared with day 29
(Figure 2E), as reflected by significant losses in the
weights of gastrocnemius muscle and ovarian adipose
tissues (Table 2). Feeding of the Fe-Lf diet attenu-
ated the cachectic status of mice. Thus, mice fed the
Fe-Lf diet had significantly (P < 0.05) higher body
weights compared to the mice fed the control diet
(Figure 2E), as reflected by significantly higher
carcass weights (Table 2).
Tamoxifen has an effect on energy homeostasis in
rodents such that it markedly decreases food intake
and body weight [42,43]. Here tamoxifen treatment
resulted in a significant (P < 0.05) loss in the body
weight of mice fed the control diet, compared to un-
treated mice fed the control diet (Figure 2E). Mice fed
the Fe-Lf diet and treated with tamoxifen had signifi-
cantly (P < 0.05) higher body weights compared to
mice fed the control diet and treated with tamoxifen.
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Oral Fe-Lf attenuates tamoxifen-induced
immunosuppression as evidenced by restoration of IL-18
and IFN-γ expression
Blood samples were collected from the mice (n = 6, per
group) sacrificed on days 29, 36 and 43 in the prevention
experiment (Figure 2A). As shown in Figure 3A, mice
bearing 4T1 tumors had significantly higher levels of
serum IL-18 than the healthy control mice, at all the
indicated time points. In contrast, the serum levels of
IL-18 in mice fed the control diet and treated with tam-
oxifen were significantly (P < 0.05) lower on day 36 and
43 than those of untreated mice fed the control diet.
Feeding of the Fe-Lf diet significantly (P < 0.05) elevated
the serum IL-18 levels on days 29 and 36, compared to
the control diet. The serum levels of IL-18 in mice treated
with the combination of Fe-Lf diet and tamoxifen were
significantly higher on day 29 (P < 0.01), 36 (P < 0.01) and
43 (P < 0.001) than those of mice treated with the com-
bination of the control diet and tamoxifen. Serum levels
of IFN-γ (Figure 3B) showed a similar pattern of change
to IL-18, but the levels of serum IFN-γ in mice bearing
4T1 tumors were the similar to those in healthy controls,
and did not significantly increase over time.
Sections of the intestines of mice killed on day 43 in
the prevention experiment (Figure 2A) were stained with
Abs against IL-18 and IFN-γ, and the numbers of cells
in the intestinal lamina propria expressing IL-18 and
IFN-γ were enumerated. As shown in Figure 3C, tamoxi-
fen therapy significantly (P < 0.001) reduced the number
of IL-18+ cells in the lamina propria, whereas in contrast
the Fe-Lf diet significantly (P < 0.001) increased the
number of IL-18+ cells, compared to that of mice fed the
control diet. Further, the Fe-Lf diet attenuated the re-
duction in the number of IL-18+ cells caused by tamoxi-
fen therapy, resulting in a significantly (P < 0.05) higher
number of IL-18+ cells in mice treated with the combin-
ation of Fe-Lf and tamoxifen than that of mice treated
with the combination of control diet and tamoxifen.
Similarly, tamoxifen therapy significantly (P < 0.05)
reduced the number of IFN-γ+ cells in the lamina pro-
pria (Figure 3C). In contrast, the Fe-Lf diet significantly
(P < 0.05) increased the number of IFN-γ+ cells, and
attenuated the reduction in the number of IFN-γ+ cells
in the lamina propria caused by tamoxifen therapy.
Identity of cells in the intestinal lamina propria that
contain high levels of Lf
We previously demonstrated that bovine Fe-Lf is taken
up by cells residing in the lamina propria and Peyer’s
patches [36]. In agreement, cells of the intestinal villi of
Table 2 Body, tumor, organ and tissue weights1
Control diet Control diet + TAM Lf diet Lf diet + TAM
(n = 6) (n = 6) (n = 6) (n = 6)
Body weight (g) 16.9 ± 1.1 13.9 ± 0.42 18.1 ± 1.1 15.0 ± 0.52,3,4
Carcass body weight (g)5 16.4 ± 1.3 13.6 ± 0.42 18.0 ± 1.22 14.8 ± 0.52,3,4
Tumor (mg)6 309.4 ± 32.9 216.3 ± 26.72 194.7 ± 19.82 146.2 ± 17.32,3,4
Liver (mg)7 1262.5 ± 44.1 1215.7 ± 109.5 1318.2 ± 40.8 1285.2 ± 86.9
Lung (mg)8 389.2 ± 37.1 297.2 ± 19.42 309.3 ± 27.92 281.3 ± 22.22
Gastrocnemius muscle (mg) 91.8 ± 6.7 77.9 ± 8.2 99.6 ± 4.2 88.4 ± 5.02,3,4
Ovarian adipose tissue (mg) 26.1 ± 2.5 22.5 ± 1.72 28.1 ± 1.3 25.0 ± 1.83
1Tumors, lungs, livers, small intestines, gastrocnemius muscles and ovarian adipose tissues of mice in the prevention study were excised at day 43 and weighed.
Data are expressed as means ± SD. Statistical significance was determined by one way ANOVA followed by Dunnett’s test. 2P < 0.05 versus the mice fed the
control diet; 3P < 0.05 versus the mice fed the control diet and treated with TAM; 4P < 0.05 versus the mice fed Lf diet. 5Calculated according to the formula: body
weight – tumor weight. 6Tumor refers to primary tumor. 7Liver weight includes metastatic tumors. 8Lung weight includes metastatic tumors. TAM, tamoxifen.
(See figure on previous page.)
Figure 2 Fe-Lf augments tamoxifen therapy to suppress the formation and growth of 4T1 tumors and their metastasis to livers and
lungs. A,B: Fe-Lf augments tamoxifen therapy to suppress the formation and growth of 4T1 tumors. A: In the prevention experiment, 6 mice
from each group were randomly killed for sampling on days 29, 36, and 43 following placement on diets and the start of administration of
tamoxifen (TAM). Tumor size was measured every two days. B: In the treatment experiment, tamoxifen (TAM) was administered to the mice
14 days after injection of tumor cells. Each group had 6 mice, and tumor size was measured every two days. C,D: Fe-Lf augments tamoxifen
therapy to suppress metastasis to livers and lungs. Mice in the prevention experiment were euthanized on day 43, and their livers and lungs
removed. The livers were sectioned and stained with HE. The numbers of metastatic tumor nodules in liver sections (C) and the number of
metastatic tumors on the surface of lungs (D) were counted, respectively. Results are expressed as the mean value ± SD. “*” P < 0.05 or “**” P
<0.001 versus the group fed the control diet, “†” P < 0.05 versus the group fed the control diet and treated with tamoxifen, and “‡” P < 0.05
versus the group fed the Fe-Lf diet. E: Fe-Lf attenuates loss of body weight caused by cancer cachexia and tamoxifen therapy, and inhibits
tamoxifen-induced reductions of IL-18 and IFN-γ in sera and intestinal cells. The mice in the prevention experiment were weighed every two
days. “*” P < 0.05 versus the group fed the control diet, “†” P < 0.05 versus the group fed the control diet and treated with tamoxifen (TAM).
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mice fed the Fe-Lf diet contained high levels of Lf
(Figure 4A), as compared to mice fed the control diet.
Intestinal villus sections were double-stained with an Ab
against bovine Lf and Abs against different leukocyte
markers, followed by a FITC or alexa fluor 568-
conjugated secondary Ab, respectively, to identify the
cells that contained high levels of Lf. Representative
illustrations show macrophages, and NK cells that con-
tain high levels of Lf. The percentages of each leukocyte
subset that had high levels of Lf were calculated
(Figure 4A), indicating that macrophages, NK and T cells
within the intestinal lamina propria contained the high-
est levels of Lf.
Identity of cells in Peyer’s patches that contain high
levels of Lf
Peyer’s patches of mice fed the Fe-Lf diet contained
high levels of Lf (Figure 4B), as compared to mice fed
the control diet. Representative illustrations show
CD3+ T cells, and B cells that contained high levels of
Lf. The percentages of each leukocyte subset that had
high levels of Lf were calculated (Figure 4B), indicat-
ing that B and T cells in the Peyer’s patches contained
the highest levels of Lf.
Intestinal leukocytes that contain high levels of Lf
migrate to distal tumors
The possibility that intestinal leukocytes which con-
tained high levels of Lf might migrate to distal tumors
was examined. 4T1 breast tumors were collected from
mice in the prevention experiment (Figure 2A) which
had been fed for 28 days with the control diet or the Fe-
Lf diet. Tumor sections were double-stained with Abs
against various leukocyte subset markers, and against
bLf. Very few leukocytes could be detected in the tumors
of mice fed the control diet (data not shown). In con-
trast, leukocytes were readily detected in the tumors of
mice fed the Fe-Lf diet (Figure 4C). T, B and NK cells
present in tumors stained positively for bLf, suggesting
that these three types of leukocytes, but not macro-
phages and dendritic cells, had migrated to the tumors
from the intestine.
Discussion
The present study has demonstrated that oral administra-
tion of Fe-Lf improves tamoxifen therapy in a mouse model
of basal-like breast cancer, and overcomes tamoxifen-
mediated immunosuppression. Orally fed Fe-Lf augmented
tamoxifen therapy to delay the appearance of palpable
tumors in the breasts of female Balb/c mice, and inhibited
their subsequent growth. It augmented tamoxifen-mediated
inhibition of the metastasis of tumors to the liver and lung.
Oral Fe-Lf increased serum levels of IL-18 and IFN-γ and
the numbers of cells expressing IL-18 and IFN-γ in intes-
tinal tissues, and prevented their reduction by tamoxifen. It
attenuated the loss of body weight caused by tamoxifen
and cancer cachexia.
The 4T1 tumor cell line employed here was derived
from the 410.4 cell line obtained from a spontaneously
arising mouse mammary epithelial tumor [41,44], and
hence cannot be regarded as a tumor that has been
forced to acquire tamoxifen-resistance. It is resistant to
the effects of tamoxifen by virtue of the fact that it in-




Figure 3 Inhibition of reductions of IL-18 and IFN-γ in sera and
intestinal cells. Blood and intestinal samples were collected from
the mice in the prevention when they were killed on days 29, 36
and 43. A,B: The serum levels of IL-18 (A) and IFN-γ (B) were
measured in the above mice and a group of 6 healthy control mice.
C: The intestinal tissues were sectioned, immunostained with Abs
against mouse IL-18 and IFN-γ, respectively, and examined by
microscopy. IL-18+ and IFN-γ+ cells were counted in 10 fields. Results
are expressed as the mean value ± SD. “*” P < 0.05 and “**” P < 0.001
versus the group fed the control diet, “†” P < 0.05 versus the group
fed the control diet and treated with tamoxifen, and “‡” P < 0.05
versus the group fed the Fe-Lf diet.










































Figure 4 Oral administration of Fe-Lf leads to high levels of Lf in leukocytes in the lamina propria and Peyer’s patches, which migrate
to tumors. A,B: Identification of leukocyte subsets in the lamina propria (A) and Peyer’s patches (B) that contain high levels of Lf. Representative
illustrations were taken on day 43 of intestinal villus and Peyer’s patch sections, respectively, from mice in the prevention experiment fed with
control and Fe-Lf diets. Sections were immunostained with FITC-conjugated (green) Abs against bovine Lf. The anti-Lf Ab-stained intestinal villus
sections were further stained with Abs against markers for macrophages, NK cells, T cells, B cells and dendritic cells. Illustrated are (A) intestinal
sections double-stained with an anti-Lf Ab (green), and Abs (red) against macrophages and NK cells, and (B) Peyer’s patch sections double-
stained with an anti-Lf Ab (green), and Abs (red) against T cells and B cells. Magnification, x200. Arrows point to the double-stained cells. The
number of double-stained cells of each leukocyte subset was counted, and the percentage of each subset was calculated and plotted as a pie
chart. C: Phenotyping of Lf-laden leukocytes that infiltrate the tumors of mice fed the Fe-Lf diet. Sections of tumors on day 29 taken from mice in
the prevention experiment fed the control or Fe-Lf diets. Tumor sections were immunostained with a FITC-conjugated (green) anti-Lf Ab (left
panel), followed by Abs (red) against leukocyte subset markers (right panel) for T cells, macrophages, B cells, NK cells and dendritic cells, as indicated.
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accordingly does not respond to estrogen [38]. Thus,
the study describes the impact of co-treatment with
Lf and tamoxifen on the development of established
ER-ve disease.
The anti-tumor activity of Lf is largely dependent on
its ability to stimulate anti-tumor immunity when taken
orally, by promoting both innate and adaptive immune
responses [33,45]. Each of the Fe-Lf-induced cytokines
IL-18 and IFN-γ might be expected to play a role in
Fe-Lf-mediated antitumor immunity. Thus, orally admi-
nistered Lf was previously reported to exhibit antitumor
activity through production of IL-18 in the intestinal mu-
cosa [46]. Iron-saturated bLf was chosen for the current
study, as we have previously shown that it has superior
antitumor activity compared to native bLf when com-
bined with chemotherapeutic agents [36]. When fed to
C57BL6 mice bearing a variety of different tumor types, it
increased antitumor cytotoxicity, tumor apoptosis and the
infiltration of tumors by leukocytes. It bound to the intes-
tinal epithelium and was preferentially taken up within
Peyer’s patches. It increased the production of Th1 and
Th2 cytokines within the intestine and tumor, including
TNF, IFN-γ, as well as nitric oxide that have been
reported to sensitize tumors to chemotherapy. Import-
antly, it restored both red and white peripheral blood
cell numbers depleted by chemotherapy, potentially
fortifying the mice against cancer [36]. The presence of
iron may have several beneficial effects, including ren-
dering Fe-Lf more resistant to proteolysis as it passes
through the gastrointestinal tract [47], and enhancing
lymphocyte function [48].
Here we further demonstrated that oral ingestion of
bovine Fe-Lf leads to increases in the Lf content of
macrophages, NK and T cells in the intestinal lamina
propria, and B and T cells in Peyer’s patches. An inter-
esting phenomenon was the finding that many of the T
and B cells, and NK cells that infiltrated into tumors in
response to feeding of Fe-Lf contained high levels of Lf.
The most plausible explanation is that these cells are
derived from the populations of cells in the intestine that
contain high levels of Lf [36,49].
Reanalysis of the results of the Royal Marsden Hospital
study of primary breast cancer prevention [50] showed
that obese women treated with tamoxifen gained signifi-
cantly less body weight over a 6-year period than obese
women given placebo, indicating that tamoxifen can
cause weight loss [51]. Tamoxifen has an effect on en-
ergy homeostasis in rodents such that it markedly
decreases food intake and body weight [42,43]. Tamoxifen-
induced anorexia in rats was associated with fatty acid
synthase inhibition in the ventromedial nucleus of the
hypothalamus and accumulation of malonyl-CoA [51].
Tamoxifen induces rapid atrophy and metaplasia in mouse
stomach [52]. In the present study, body weight loss was
observed, particularly in the first week after tamoxifen ad-
ministration in mice fed the control diet. The Fe-Lf diet
attenuated the body weight loss induced by tamoxifen.
The 4T1 model of metastatic breast cancer represents
a model of cancer cachexia, which is a serious problem
for cancer patients as it physically weakens patients and
reduces their response to treatment. Here, we also
showed that oral Fe-Lf attenuated cancer cachexia, as
evidenced by reduced loss of body weight, and increased
weights of gastrocnemius muscle and ovarian adipose
tissue in tumor-bearing animals. The anti-tumor activity
of Fe-Lf may partly contribute to the ability to inhibit
cachexia, as the sizes of primary and metastatic tumors
were significantly smaller in Fe-Lf-treated mice, thus re-
ducing energy wasting by tumor cells. Effects of Fe-Lf in
preventing fatty acid synthase inhibition and accumula-
tion of malonyl-CoA in the hypothalamus, and stomach
atrophy may also contribute, but additional studies will
be required to determine their relevance.
Tamoxifen forms DNA adducts in human colon after
administration, and may elevate the risk of gastrointes-
tinal cancers [53]. It inhibits the growth of normal
human colon epithelial cells [54]. bLf has the potential
to improve the overall physiological condition due to
its beneficial effects on the gut epithelium, as it has
been shown to inhibit chemically-induced carcinogen-
esis in the colon [55], and human and bovine Lf stimu-
late the proliferation and differentiation of crypt cells
and enterocytes [56,57]. It improves the microbial in-
testinal environment by inhibiting the growth of patho-
gens and stimulating the establishment of beneficial
microflora [58].
The dose of Fe-Lf used in the present study equates to
a readily consumable dose of 2.5 g/day for humans,
based on equivalent surface area. The dose of tamoxifen
used equates to a human dose of 25 mg every two days,
which is slightly less than the 20 mg/day dose given to
breast cancer patients. The results indicated that Fe-Lf
was slightly superior to tamoxifen in inhibiting the
growth of tumors, albeit the difference was not signifi-
cant. The added effects of tamoxifen and Fe-Lf in inhi-
biting the growth of ER-ve 4T1 cells can be explained by
the chemotherapeutic properties of tamoxifen, and the
ability of Fe-Lf to stimulate anti-tumor immunity and
overcome tamoxifen-induced immunosuppression.
Conclusions
In conclusion, Fe-Lf augments the chemotherapeutic ef-
ficacy of tamoxifen in the treatment of ER-ve breast can-
cer as evidenced by a delay in tumor formation, and
inhibition of tumor growth and metastasis. It overcomes
tamoxifen-induced impairment of the immune response,
and attenuates body weight loss due to tamoxifen ther-
apy and cancer-associated cachexia, thus fortifying the
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tumor-bearing mice. Iron-enriched bovine Lf is a com-
paratively inexpensive natural product, which has proven
to exhibit no adverse toxicity [59]. The above panoply of
features indicate that bovine Fe-Lf might be a promising
and attractive supplement to add to tamoxifen treatment
to delay or inhibit cancer relapse due to the outgrowth
of tumors that no longer respond to the anti-estrogenic
effects of tamoxifen.
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